Treatment of prostate carcinoma with (Galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates

Biomaterials

Volumn 33, Issue 7, 2012, Pages 2260-2271

  Yang, Yang ^a   Zhou, Zhou ^a   He, Shuang ^a   Fan, Tingting ^a   Jin, Yun ^a   Zhu, Xi ^a   Chen, Chunhui ^a   Zhang, Zhi rong ^a   Huang, Yuan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

5 Fluorouracil; G3 C12 peptide; Gal 3 targeted HPMA copolymer (G3 C12) 5 Fu conjugates; Human PC 3 prostate carcinoma cells

Indexed keywords

5-FLUOROURACIL; 5-FLUOROURACIL (5-FU); ANTI-TUMOR ACTIVITIES; ANTI-TUMOR AGENTS; BINDING PEPTIDE; BLOOD CIRCULATION; CARBOHYDRATE-RECOGNITION DOMAINS; CELL MIGRATION; DRUG DELIVERY SYSTEM; FLUOROURACIL; HPMA COPOLYMERS; HUMAN TUMOR CELLS; IN-VITRO; METHACRYLAMIDES; MICE MODELS; MODEL DRUGS; NON-TARGETED; NUDE MICE; POTENTIAL BINDING SITES; PROSTATE CANCERS; PROSTATE CARCINOMA; TUMOR ACCUMULATION; TUMOR XENOGRAFTS;

CARBOHYDRATES; CARDIOVASCULAR SYSTEM; CELL DEATH; DISEASES; DRUG DELIVERY; MAMMALS; ONCOLOGY; PEPTIDES; TUMORS;

COPOLYMERS;

FLUOROURACIL; GALECTIN 3; IODINE 131; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL STRUCTURE; CHROMOSOME CONDENSATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG LIVER LEVEL; DRUG SCREENING; ENDOCYTOSIS; FLUORESCENCE; HUMAN; HUMAN CELL; INTERNALIZATION; LUNG; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; POLYMER PRODUCTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; SPLEEN;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FLUOROURACIL; GALECTIN 3; HUMANS; MALE; MATERIALS TESTING; METHACRYLATES; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; POLYMERS; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION;

MUS; MUS MUSCULUS;

EID: 84855754743     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.12.007     Document Type: Article

References (33)

1. Bogenrieder T., Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003, 22:6524-6536.
2. Laufer M., Denmeade S.R., Sinibaldi V.J., Carducci M.A., Eisenberger M.A. Complete androgen blockade for prostate cancer: what went wrong?. JUrol 2000, 164:3-9.
3. Gilligan T., Kantoff P.W. Chemotherapy for prostate cancer. Urology 2002, 60:94-100.
4. Ríhová B. Receptor-mediated targeted drug or toxin delivery. Adv Drug Deliv Rev 1998, 29:273-289.
5. Liu J., Kopečková P., Bühler P., Wolf P., Pan H., Bauer H., et al. Biorecognition and subcellular trafficking of HPMA copolymer anti-PMSA antibody conjugates by prostate cancer cells. Mol Pharm 2009, 6:959-970.
6. 3 binding peptides for tumor targeting. JControl Release 2006, 114:175-183.
7. Greish K., Ray A., Bauer H., Larson N., Malugin A., Pike D., et al. Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy. JControl Release 2011, 151:263-270.
8. Shamay Y., Paulin D., Ashkenasy G., David A. E-selectin binding peptide-polymer-drug conjugates and their selective cytotoxicity against vascular endothelial cells. Biomaterials 2009, 30:6460-6468.
9. Zou J., Glinsky V.V., Landon L.A., Matthews L., Deutscher S.L. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis 2005, 26(2):309-318.
10. Inohara H., Akahani S., Koths S., Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996, 56:4530-4534.
11. Wang L., Inohara H., Pienta K.J., Raz A. Galectin-3 is a nuclear matrix protein which binds RNA. Biochem Biophys Res Commun 1995, 217:292-303.
12. Raz A., Zhu D.G., Hogan V., Shah N., Raz T., Karkash R., et al. Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer 1990, 46:871-877.
13. 111In-labeled galectin-3 binding peptide in prostate carcinoma. Nucl Med Biol 2009, 36:137-146.
14. Rejmanova P., Labsky J., Kopeček J. Aminolyses of monomeric and polymeric p-nitrophenyl esters of methacryloylated amino acids. Makromol Chem 1977, 178:2159-2168.
15. Rihova B., Bilej M., Vetvicka V., Ulbrich K., Strohalm J., Kopecek J., et al. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin. Immunogenicity, and effect on haematopoietic stem cells in bone marrow invivo and mouse splenocytes and human peripheral blood lymphocytes invitro. Biomaterials 1989, 10:335-342.
16. Lammers T., Peschke P., Kühnlein R., Subr V., Ulbrich K., Debus J., et al. Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. JControl Release 2007, 117:333-341.
17. Omelyanenko V., Kopečková P., Gentry C., Kopeček J. Targetable HPMA copolymer-adriamycin conjugates: recognition, internalization, and subcellular fate. JControl Release 1998, 53:25-37.
18. Yuan F., Chen F., Xiang Q.Y., Qin X., Zhang Z.R., Huang Y. Synthesis and characterization of HPMA copolymer-5-FU conjugates. Chin Chem Lett 2008, 19:137-140.
19. Rathi R., Kopečková P., Rihova B., Kopeček J. N-(2-hydroxypropyl) methacrylamide copolymers containing pendant saccharide moieties: synthesis and bioadhesive properties. JPolym Sci Part A Polym Chem 1991, 29:1895-1902.
20. Nan A., Ghandehari H., Hebert C., Siavash H., Nikitakis N., Reynolds M., et al. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck. JDrug Target 2005, 13:189-197.
21. Ruttekolk I.R., Duchardt F., Fischer R., Wiesmüller K.H., Rademann J., Brock R. HPMA as a scaffold for the modular assembly of functional peptide polymers by native chemical ligation. Bioconjug Chem 2008, 19:2081-2087.
22. Rademaker-Lakhai J.M., Terret C., Howell S.B., Baud C.M., De Boer R.F., Pluim D., et al. Aphase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 2004, 10:3386-3395.
23. Meerum Terwogt J.M., ten Bokkel Huinink W.W., Schellens J.H., Schot M., Mandjes I.A., Zurlo M.G., et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 2001, 12:315-323.
24. Nishiyama N., Nori A., Malugin A., Kasuya Y., Kopecková P., Kopecek J. Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells. Cancer Res 2003, 63:7876-7882.
25. Satchi-Fainaro R., Puder M., Davies J.W., Tran H.T., Sampson D.A., Greene A.K., et al. Target angiogenesis a conjugate HPMA copolymering angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004, 10:255-261.
26. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
27. Ríhová B., Kubácková K. Clinical implications of N-(2-hydroxypropyl) methacrylamide copolymers. Curr Pharm Biotechnol 2003, 4:311-322.
28. Yuan F., Qin X., Zhou D., Xiang Q.Y., Wang M.T., Zhang Z.R., et al. Invitro cytotoxicity, invivo biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates. Eur J Pharm Biopharm 2008, 70:770-776.
29. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2:750-763.
30. Kopansky E., Shamay Y., David A. Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer. JDrug Target 2011, 19:933-943.
31. Mammen M., Choi S.K., Whitesides G.M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998, 37:2754-2794.
32. Liu J., Bauer H., Callahan J., Kopecková P., Pan H., Kopecek J. Endocytic uptake of a large array of HPMA copolymer: elucidation into the dependence on the physicochemical characteristics. JControl Release 2010, 143:71-79.
33. Glinsky G.V., Price J.E., Glinsky V.V., Mossine V.V., Kiriakova G., Metcalf J.B. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines. Cancer Res 1996, 56:5319-5324.